Global Liver Diseases Therapeutics Market 2015-2019

肝臓病治療の世界市場:非アルコール性脂肪性肝疾患、肝硬変、肝癌、肝炎

◆タイトル:Global Liver Diseases Therapeutics Market 2015-2019
◆商品コード:IRTNTR7566
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年9月30日
◆ページ数:95
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、肝臓病治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、肝臓病治療の世界市場規模及び予測、種類別分析、市場シェア、地域別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About liver diseases
Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Hepatitis is the largest segment among these diseases, of which hepatitis C is the biggest and fastest growing segment. The liver diseases caused by viral infections, alcoholism, obesity, diabetes, among many other reasons. Some of the diseases are not curable such as liver cirrhosis or non-alcoholic fatty liver disease, and are usually not diagnosed early. This leads to the substantial damage of the liver, which proves to be life-threatening. Some types of hepatitis are preventable or treatable by using vaccines and indicated drugs.

Technavio’s analysts forecast the global liver diseases therapeutics market to grow at a CAGR of 15.61% over the period 2014-2019.

[Covered in this report]
This report covers the present scenario and the growth prospects of the global liver diseases therapeutics market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of liver diseases.

Based on disease indication, the market is segmented as follows:
• Non-alcoholic fatty liver disease (includes non-alcoholic steatohepatitis)
• Liver cirrhosis
• Liver cancer
• Hepatitis (Hepatitis A, B, and C)

This report includes a discussion of the market in the following three regions:
• Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
• EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE

• APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India.
Technavio’s report, Global Liver Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the global liver diseases therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key regions]
• Americas
• APAC
• EMEA

[Key vendors]
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck

[Other prominent vendors]
• AbbVie
• Achillion Pharmaceuticals
• Advinus
• Angion Biomedica
• AstraZeneca
• Bayer
• BiOrion
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celsion
• Conatus
• Digna Biotech
• Dynavax Technologies
• Eli Lilly
• Galectin Therapeutics
• Genfit
• GenKyoTex
• Isis Pharmaceuticals
• Janssen Pharmaceuticals
• Kaketsuken
• La Jolla Pharmaceutical
• LG Life Sciences
• Mitsubishi Tanabe Pharma
• Nitto Denko
• Novartis
• Onyx Pharmaceuticals
• Phenex Pharmaceuticals
• Promedior
• Promethera Biosciences
• ProMetic Life Sciences
• Raptor Pharmaceuticals
• Shenzhen Kangtai Biological Products
• TCM Biotech
• Tobira Therapeutics
• VBL Therapeutics
• Verva Pharmaceuticals
• Virobay
• Zafgen

[Market Driver]
• Increased prevalence of liver diseases
• For a full, detailed list, view our report

[Market challenge]
• Multiple patent expiries
• For a full, detailed list, view our report

[Market trend]
• Growing public awareness
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Disease overview
Hepatitis
Liver cancer
Liver cirrhosis
Nonalcoholic fatty liver disease

PART 06: Market landscape
Global liver diseases therapeutics market

PART 07: Market segmentation by disease
Hepatitis
Liver cirrhosis
Liver cancer
Nonalcoholic fatty liver disease

PART 08: Global hepatitis therapeutics market
Global hepatitis A therapeutics market
Global hepatitis B therapeutics market
Global hepatitis C therapeutics market

PART 09: Global liver cancer therapeutics market

PART 10: Global nonalcoholic fatty liver disease therapeutics market

PART 11: Global liver cirrhosis therapeutics market

PART 12: Market segmentation by type of molecule
Biologics
Small molecules

PART 13: Geographical segmentation
Liver diseases therapeutics market in Americas
Liver diseases therapeutics market in EMEA
Liver diseases therapeutics market in APAC

PART 14: Market drivers

PART 15: Impact of drivers

PART 16: Market challenges

PART 17: Impact of drivers and challenges

PART 18: Market trends

PART 19: Vendor landscape
Competitive scenario
Market share analysis 2014
Other and future prominent vendors

PART 20: Key vendor analysis
F. Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck

PART 21: Appendix
List of abbreviations
Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Hepatitis: Mode of transmission and incubation period
Exhibit 03: Various modes of transmission of hepatitis B viral infection
Exhibit 04: Various modes of transmission of hepatitis C viral infection
Exhibit 05: Worldwide endemicity of hepatitis A virus infection
Exhibit 06: Worldwide endemicity of hepatitis B virus infection
Exhibit 07: Prevalence of hepatitis B in US 2005-2013
Exhibit 08: Prevalence of hepatitis C across regions
Exhibit 09: Antibodies indicating hepatitis
Exhibit 10: Tests for viral proteins and genetic material
Exhibit 11: Screening tests for hepatitis C infection
Exhibit 12: Recommended dosages and schedules of hepatitis A vaccines
Exhibit 13: Global liver diseases therapeutics market 2014-2019 ($ billions)
Exhibit 14: Five forces analysis
Exhibit 15: Global liver diseases therapeutics market by disease 2014
Exhibit 16: Global hepatitis therapeutics market 2014-2019 ($ millions)
Exhibit 17: Global hepatitis A therapeutics market 2014-2019 ($ millions)
Exhibit 18: Global hepatitis B therapeutics market 2014-2019 ($ millions)
Exhibit 19: Global hepatitis C therapeutics market 2014-2019 ($ millions)
Exhibit 20: Global hepatitis therapeutics market by type 2014
Exhibit 21: Global liver cancer therapeutics market 2014-2019 ($ millions)
Exhibit 22: Global liver cancer therapeutics market: Challenges and drivers
Exhibit 23: Global nonalcoholic fatty liver disease therapeutics market 2014-2019 ($ millions)
Exhibit 24: Global nonalcoholic fatty liver disease therapeutics market: Challenges and drivers
Exhibit 25: Global liver cirrhosis therapeutics market 2014-2019 ($ millions)
Exhibit 26: Global liver cirrhosis therapeutics market: Challenges and drivers
Exhibit 27: Global liver diseases therapeutics market by geography 2014
Exhibit 28: Liver diseases therapeutics market in Americas ($ billions)
Exhibit 29: Liver diseases therapeutics market in EMEA ($ billions)
Exhibit 30: Liver diseases therapeutics market in APAC ($ billions)
Exhibit 31: Impact of drivers
Exhibit 32: Impact of drivers and challenges
Exhibit 33: Johnson & Johnson: Business segmentation



【掲載企業】

F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Achillion Pharmaceuticals, AbbVie, Advinus, Angion Biomedica, AstraZeneca, Bayer, BiOrion, Boehringer Ingelheim , Bristol-Myers Squibb, Celsion, Conatus, Digna Biotech, Dynavax Technologies, Eli Lilly, Galectin Therapeutics, Genfit, GenKyoTex, Isis Pharmaceuticals, Janssen Pharmaceuticals, La Jolla Pharmaceutical, LG Life Sciences, Kaketsuken, Mitsubishi Tanabe Pharma, Nitto Denko, Novartis, Onyx Pharmaceuticals (a subsidiary of Amgen), Phenex Pharmaceuticals, Promedior, Promethera Biosciences, ProMetic Life Sciences, Raptor Pharmaceuticals, Shenzhen Kangtai Biological Products, TCM Biotech, Tobira Therapeutics, VBL Therapeutics, Verva Pharmaceuticals, Virobay, Zafgen.

【資料のキーワード】

肝疾患、肝臓病治療、非アルコール性脂肪性肝疾患、肝硬変、肝癌、肝炎、治療薬、製薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[肝臓病治療の世界市場:非アルコール性脂肪性肝疾患、肝硬変、肝癌、肝炎] (Global Liver Diseases Therapeutics Market 2015-2019 / IRTNTR7566)販売に関する免責事項
[肝臓病治療の世界市場:非アルコール性脂肪性肝疾患、肝硬変、肝癌、肝炎] (Global Liver Diseases Therapeutics Market 2015-2019 / IRTNTR7566)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆